MyoRegulator

Direct Nerve Stimulation Using MyoRegulator System Seen to Reduce Spasticity in Mice with Spinal Injury

Treatment with PathMaker Neurosystemsā€™ anodal transā€spinal direct current stimulation (tsDCS), aĀ non-invasive direct nerve stimulation tool called MyoRegulator, was found to effectively easeĀ spasticity in mice with spinal cord injury, a study reports. A link between the ability to control muscle contraction and the levels of a specific neuronal…

WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity

WeHealth by Servier and PathMaker Neurosystems have established a new partnership to develop and commercialize the first neuromodulation technology for noninvasive treatment of spasticity, the companies announced. The agreementĀ establishes an exclusive worldwide distribution arrangement, except for the U.S. and Japan, for PathMakerā€™sĀ MyoRegulator. The MyoRegulator uses two pairs of…

PathMaker Neurosystems, Developing MyoRegulator for Spasticity, Named Startup of Year at French-American Business Gala

PathMaker Neurosystems, which specializes in non-invasive devices to treat chronic neuromotor disorders, won theĀ 2018 French-American Business (FAB) AwardĀ in the startup/small company category. PathMaker, based in Boston, is developed and testingĀ MyoRegulator, a potential treatment forĀ muscle spasticity in people withĀ multiple sclerosis (MS), cerebral palsy and other chronic conditions.

BpiFrance Awards PathMaker Grant to Develop MyoRegulator, Device to Treat Spasticity

The French economic promotionĀ agencyĀ BpifranceĀ has awarded Boston-basedĀ PathMaker NeurosystemsĀ a grant to finance theĀ development of itsĀ MyoRegulator, a noninvasiveĀ neurotherapy technology to treatĀ conditions linked toĀ neural pathway disruption, includingĀ neuromotor spasticity in patients with multiple sclerosis (MS). Through the Programme d’Investissements d’Avenir (PIA-1), an investment program offered by Bpifrance, the Ā grant ā€” whose…

PathMaker, French Institute to Team on MyoRegulator Neuro-stimulation Clinical Trials

PathMaker Neurosystems and the Brain and Spine InstituteĀ (ICM) in Paris will collaborate on human clinical trials to secure CE Mark clearance for PathMakerā€™s MyoRegulatorĀ PM-2200, a noninvasiveĀ neurotherapy technology to treatĀ conditions linked toĀ neural pathway disruption, including multiple sclerosis (MS). CE Mark ā€”Ā whichĀ stands for “ConformitĆ© EuropĆ©enne,” or European Conformity…

PathMaker Wins Innovation Prize for Neurotherapies to Treat Spasticity, Muscle Weakness

PathMaker Neurosystems is the winnerĀ of the Universal BiotechĀ Innovation Prize 2016Ā for its innovative, non-invasiveĀ neurotherapy technologies to treatĀ conditions linked toĀ neural pathway disruption, including multiple sclerosis (MS). The selectionĀ was announced at Innovation Days, an international event honoring the best in the life sciences andĀ heldĀ in Paris on Oct. 3ā€“4. Launched in 2009 byĀ a…

PathMaker Launches Clinical Trial of MyoRegulator to Treat Spasticity, Common in MS

PathMaker Neurosystems, Inc.,Ā recently announced the launch of anĀ Institutional Review Board (IRB)-approvedĀ clinical trial, in partnership with Northwell Health (formerly North Shore-LIJ Health System) andĀ The Feinstein Institute for Medical Research,Ā to evaluate the safety and efficacy ofĀ MyoRegulator for the treatment of spasticity, one of the most common symptoms in multiple sclerosis…

New Muscle Spasticity Therapy Under Priority Review by FDA

PathMaker Neurosystems Inc., a clinical-stage neuromodulation company focused on non-invasive therapies for neuromotor disorders, recently announced that the U.S. Food and Drug Administration (FDA) has granted the companyā€™s MyoRegulatorā„¢ PM-2200 systemĀ the Expedited Access Pathway (EAP) designation and priority processing status. The MyoRegulator is the first product of PathMaker…